SecBot SecBot
8-K ·Filed Nov 5, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 5/10
Horizondays Processed11d 11h ago SEC0001193125-26-449853
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The cash update is overshadowed by the same-day equity offering, which will dilute holders. Monitor the offering pricing and size in the final prospectus; the company's cash runway and first commercial launch ramp will be key catalysts.

DirectionBearish
Confidencehigh
Horizondays

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.22
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.70%
T+5 · $1.43 · next T+20 in 20d
Vs SPY
+15.10%
α at T+5
Latest observation
+17.93%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $1.22entry
  2. T+1 · 8d ago +24.28%α +21.91% · $1.51
  3. T+5 · 4d ago +17.70%α +15.10% · $1.43
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals filed an 8-K with preliminary Q3 2026 cash of $48.4M, up from $37.7M at Q1 end, alongside a same-day $300M shelf offering. The cash update follows the October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP, but the concurrent equity offering signals ongoing capital needs for a pre-revenue biotech with a going concern warning.

Key Facts

  • Preliminary cash, cash equivalents and short-term investments as of September 30, 2026 were approximately $48.4 million.
  • A same-day 424B5 filing (November 5, 2026) initiates an underwritten public offering of common stock from the $300M shelf, with share count and price TBD.
  • FDA granted accelerated approval for VOCERYQ (INO-3107) on October 30, 2026, the company's first commercial product.
  • Prior Q1 2026 cash balance was $37.7M (excluding $16M April offering); the company had a going concern warning.
  • No revenue reported for Q3 2026; the company is pre-revenue with a net loss of $19.7M in Q1 2026.
  • The 8-K provides only a preliminary cash estimate, not full Q3 financial results.

Financial Impact

Preliminary cash of $48.4M as of September 30, 2026, up from $37.7M at March 31, 2026 (excluding $16M April offering). The concurrent equity offering will dilute existing shareholders; proceeds are undisclosed.

cashdilutionshare count

Risk Factors

  • Dilution from the concurrent equity offering, with share count and price undisclosed.
  • Pre-revenue status with ongoing operating losses and a going concern warning.
  • Commercial execution risk for VOCERYQ as a first product launch.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449853
Document: 0001193125-26-449853-index-headers.html0001193125-26-449853
Document: 0001193125-26-449853-index.html0001193125-26-449853
Document: 0001193125-26-449853.txt0001193125-26-449853
8-K Data (Synthetic)0001193125-26-449853

Track record

20 reports on INO

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026